NCT03884075View on ClinicalTrials.gov

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

October 2, 2026

Conditions
Non-Alcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease
Interventions
DRUG

Semaglutide

Semaglutide injection once weekly

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH